glp 1 fda ban on Compounded GLP-1 Drugs: What to Know FDA bans compounded GLP-1 drugs

A review published in 2025 in the Journal of Crohns and Colitis suggests that GLP-1 medications have both metabolic and anti-inflammatory benefits for people with IBD, with early studies linking them to improved outcomes like fewer hospitalizations

Similarly, a 2024 study published in the Journal of the American Medical Association analyzed data from 16,827 patients and found that those prescribed semaglutide had a significantly higher risk of developing NAION compared to those on non-GLP-1 medications

There is limited evidence supporting this approach, and it should be reserved for severe, refractory cases under gastroenterology specialist guidance

Presented for research literature review only Zemba M et al

For external cosmetic use only PARABEN-FREE FORMULA: Made without parabens or artificial fragrances